

Climate Change, Human Health and Trade

Dr. Lutz Hegemann
President, Global Health & Sustainability
14th of November 2023


Health outcomes have improved over the past three decades but climate change threatens this progress

Notable progress and select milestones over three decades

	1990	2019
LMIC life expectancy ¹	63 years	71 years
SSA child mortality per 1000 births ²	180	76

- 2002** ■ Approval of **rotavirus vaccine** sparks downturn in associated child mortality
- 2016** ■ Global **visceral leishmaniasis** cases reduced by 60% vs. 2011 baseline³
- 2021** ■ China certified **malaria-free** by WHO

Global Malaria Deaths Per Year ⁴



We cannot fight problems of tomorrow with tools of yesterday: investment into R&D is essential



In the last decade, the private sector **donated** more than 14 billion NTD treatments


Commitments made by Novartis

2012 - London Declaration signed and committed to donate multidrug therapy for the treatment of leprosy

2018 - Malaria Summit in London: **US\$ 100 million** committed to R&D for medicines against malaria

2022 – Kigali Declaration: **US\$ 250 million** committed to R&D for medicines against NTDs and malaria

Our long-term investments have led to a robust pipeline with multiple **NCEs for climate-affected disease areas**



A multi-pronged approach to address the challenges of climate change



Baseline: Aggressive environmental targets for both own operations and supply chain (e.g., net zero)



We can create the greatest impact in the areas of innovation & access



Invest in R&D that directly targets the anticipated challenges of climate change



Ensure that medicines reach the people who need them the most through partnerships



We also have a role to play on a broader systems level



Reverse engineer our approach to healthcare to address climate-related diseases (i.e., tertiary to primary care)



Engage in prevention strategies that stall the impact of climate change at population health level (e.g., AI4HealthyCities)

A balanced trade policy is needed to maximize our impact amidst evolving climate concerns

- We are seeking a **level playing field**, without trade barriers, so that patients who need medicines can get them.
- Intellectual property is needed to **incentivize innovation** – but it must not prevent access.

Trade agreements (such as the African Continental Free Trade Area) can create impact across 4 key areas:

1

Incentivizing the creation of sustainable healthcare systems

2

Developing IP policies that enable innovation and access (e.g., non-exclusive voluntary licensing)

3

Harmonizing regulatory systems that are transparent and robust

4

Making global supply chains more efficient and resilient



Thank you